Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

In order to unravel possible mechanisms of clinical resistance to topoisomerase I inhibitors, we developed a topotecan-resistant human IGROV-1 ovarian cancer cell line, denoted IGROV(T100r), by stepwise increased exposure to topotecan (TPT). The IGROV(T100r) cell line was 29-fold resistant to TPT an...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, J., Maliepaard, M., Nooter, K., Loos, W. J., Kolker, H. J., Verweij, J., Stoter, G., Schellens, J. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150067/
https://www.ncbi.nlm.nih.gov/pubmed/9635842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150067/
https://www.ncbi.nlm.nih.gov/pubmed/9635842

Ejemplares similares